Anaergia (TSX:ANRG) Stock Faces Profit Fragility Behind Revenue Surge

Anaergia stock has been sliding for months, yet the latest numbers tell a sharper story than the share price suggests. At CA$2.26 after the first full day of trading post release, the stock reflects a market that has stayed cautious even as the company reported Q2 revenue of CA$63.9 million and its fourth straight quarter of positive adjusted earnings before interest, tax, depreciation and amortization.

The real headline is profit quality. Net income has just edged into positive territory over the last 12 months, helped by a CA$1.2 million one off gain, while the P/E multiple sits at 96.5x. That tension between fragile profitability and a rich valuation is the gap investors now need to weigh.

Like Anaergia's revenue base but uneasy about fragile profitability at a 96.5x P/E? You can compare it with companies that pair earnings quality with stronger balance sheets in our list of solid balance sheet and fundamentals stocks (12 results).

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs. Q2 2025): CA$63.9m vs. CA$32.3m (very large increase, almost 2x).
• Net Income (Excl. Extra Items, Q2 2026 vs. Q2 2025): CA$0.4m profit vs. CA$7.0m loss (shifted into profit).
• Basic EPS (Q2 2026 vs. Q2 2025): CA$0.0031 vs. a loss of CA$0.0411 per share (moved from loss to marginally positive).
• Trailing 12 Month Revenue and Net Income (to Q2 2026 vs. to Q2 2025): CA$242.2m revenue and CA$4.0m net income vs. CA$120.2m revenue and CA$58.6m loss (revenue almost doubled and results moved from loss to profit).

Prefer clean visuals instead of scrolling through dense financial tables for Anaergia? See the full picture of Anaergia's valuation at a glance in our company report for Anaergia.

Anaergia bull case hinges on execution milestones

Bulls argue Anaergia is turning a larger backlog and policy support into more predictable earnings, helped by better project execution and BOO style operations. Q2 results give some backing. Revenue almost doubled year over year to CA$63.9m and H1 revenue moved above CA$119m, which shows backlog is being converted into actual project work, especially in Italy and North America. Backlog itself increased to CA$274.9m with CA$66m of new awards, including repeat business from large counterparties such as Neogenyx Fuels and Vanguard. That supports the idea of customer validation and future revenue visibility. Profit quality also improved. Gross profit reached CA$14.5m and adjusted EBITDA was CA$1.9m, the fourth straight positive quarter, with trailing 12 month adjusted EBITDA at CA$9.7m. The first deliveries from SoCal Biomethane into California programs further support the claim that Anaergia’s BOO projects are starting to operate at scale.

Bear case focuses on profit fragility and asset drag

Bears focus on Anaergia’s weak profitability, asset risk, and capital intensity. Q2 data does not fully clear those concerns. The company still reported a net loss of CA$2.1m in the quarter and CA$6.5m for the year to date, even after four straight quarters of positive adjusted EBITDA. Gross margin sat at 22.7% and management disclosed that the Rhode Island Bioenergy Facility produced a gross margin loss of about CA$1.8m in Q2. That confirms underperforming assets are directly weighing on earnings quality. Management also flagged other operational issues, including idled assets like Charlotte and timing variability in O&M revenue. The need for a CA$20m revolving credit facility with an accordion to CA$30m underlines ongoing funding needs for a capital intensive model. Recent share price declines over 7 days, 30 days, and 90 days suggest the market is still pricing in these risks.

After a quarter that still needed a CA$20m credit line, idled assets and a one off gain, it is fair to ask whether these visible issues are the full story or just early signs of deeper strain. Review the independent risk analysis for Anaergia which shows 3 important warning signs

Stay Ahead With Anaergia Insights

If Anaergia's mix of higher revenue, thin profitability and a 96.5x P/E has your attention, register for free with Simply Wall St and add it to a Watchlist to monitor share price against fair value and keep an eye out for your preferred entry point. Once you own Anaergia or other stocks, use the Portfolio Command Center to cut through market noise and focus on the key developments that matter to your holdings. For a longer term view, tap into the Community to see how other investors are thinking about similar risks and opportunities. By spotting potential catalysts and pressure points early, you give yourself a better chance to act ahead of the wider market.

Seeking Alternatives Beyond Anaergia Now

Some stocks are building quiet breakout momentum while others risk dropping before you have even caught the move. These ideas sit under the radar for now, so consider reviewing them promptly.

• Spot potential early leaders with strong balance sheets and cash flows before they start moving sharply by reviewing the curated 13 high quality undervalued stocks.
• Track companies involved in the AI build out as demand for chips and infrastructure grows by using the focused 56 AI infrastructure stocks.
• Find income ideas that aim to keep paying you even when markets are choppy by scanning the hand picked 5 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com